Shanghai Universal BiotechLtd Valuation

Is 301166 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301166 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301166 (CN¥30.1) is trading above our estimate of fair value (CN¥21.54)

Significantly Below Fair Value: 301166 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301166?

Key metric: As 301166 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 301166. This is calculated by dividing 301166's market cap by their current revenue.
What is 301166's PS Ratio?
PS Ratio	2.2x
Sales	CN¥1.17b
Market Cap	CN¥2.75b

301166 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	-56.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 301166's PS Ratio compare to its peers?

The above table shows the PS ratio for 301166 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1x
000705 Zhejiang Zhenyuan ShareLtd	0.7x	n/a	CN¥2.8b
002788 Luyan PharmaLtd	0.2x	n/a	CN¥3.4b
002462 Cachet Pharmaceutical	0.1x	n/a	CN¥4.1b
603122 Cowealth Medical ChinaLtd	2.9x	n/a	CN¥2.9b
301166 Shanghai Universal BiotechLtd	2.2x	n/a	CN¥2.7b

Price-To-Sales vs Peers: 301166 is expensive based on its Price-To-Sales Ratio (2.2x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does 301166's PS Ratio compare vs other companies in the CN Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
601607 Shanghai Pharmaceuticals Holding	0.3x	9.5%	US$10.00b
600998 Jointown Pharmaceutical Group	0.2x	8.0%	US$3.71b
000028 China National Accord Medicines	0.2x	5.7%	US$2.22b
000950 C.Q. Pharmaceutical Holding	0.1x	10.1%	US$1.37b

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 301166 is expensive based on its Price-To-Sales Ratio (2.2x) compared to the CN Healthcare industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 301166's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301166 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 301166's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.1b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥16.51

-1.3%

-30.9%

iRay Technology

CN¥16.1b

Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.

688301

CN¥112.93

-5.6%

-30.5%

Truking Technology

CN¥4.7b

Engages in medical equipment business in China and internationally.

300358

CN¥8.01

3.2%

-32.9%